PURPOSE: The aim of the present study was to investigate possible associations of the single-nucleotide variants in six genes encoding the key molecules mediating the metformin pharmacodynamic effect with the response to treatment with metformin in patients with type 2 diabetes. METHODS: One hundred forty-eight drug-naïve patients with type 2 diabetes were included in the study. PRKAA1 rs249429, STK11 rs741765, PCK1 rs4810083, PPARGC1A rs10213440, HNF1A rs11086926, and CAPN10 rs3792269 variants were genotyped. The outcomes of the study were treatment success defined by achieving HbA1c <7 % and absolute reduction in HbAlc after 6-month metformin therapy. The relationships between genotypes and outcomes were evaluated in multivariate logistic and linear models. The level of statistical significance after Bonferroni correction was predefined as p<0.0083. RESULTS: The minor G-allele of CAPN10 rs3792269 A>G polymorphism was significantly associated with less treatment success with an odds ratio of 0.27 (95 % CI 0.12-0.62, p=0.002) per variant allele. When the reduction in HbA1c was analyzed as a quantitative trait, G-allele was nominally associated with a smaller reduction in HbA1c (per allele β=-0.26, 95 % CI -0.50 to -0.02, p=0.032). The reduction in HbA1c in minor allele carriers (24 % of study population) was smaller by 0.3 % in comparison with the major allele homozygotes. CONCLUSIONS: The present study provides the first observation of an association between a variant in CAPN10 gene and the response to metformin therapy in patients with type 2 diabetes. This observation needs to be replicated in further studies in different populations.
PURPOSE: The aim of the present study was to investigate possible associations of the single-nucleotide variants in six genes encoding the key molecules mediating the metformin pharmacodynamic effect with the response to treatment with metformin in patients with type 2 diabetes. METHODS: One hundred forty-eight drug-naïve patients with type 2 diabetes were included in the study. PRKAA1rs249429, STK11rs741765, PCK1rs4810083, PPARGC1Ars10213440, HNF1Ars11086926, and CAPN10rs3792269 variants were genotyped. The outcomes of the study were treatment success defined by achieving HbA1c <7 % and absolute reduction in HbAlc after 6-month metformin therapy. The relationships between genotypes and outcomes were evaluated in multivariate logistic and linear models. The level of statistical significance after Bonferroni correction was predefined as p<0.0083. RESULTS: The minor G-allele of CAPN10rs3792269 A>G polymorphism was significantly associated with less treatment success with an odds ratio of 0.27 (95 % CI 0.12-0.62, p=0.002) per variant allele. When the reduction in HbA1c was analyzed as a quantitative trait, G-allele was nominally associated with a smaller reduction in HbA1c (per allele β=-0.26, 95 % CI -0.50 to -0.02, p=0.032). The reduction in HbA1c in minor allele carriers (24 % of study population) was smaller by 0.3 % in comparison with the major allele homozygotes. CONCLUSIONS: The present study provides the first observation of an association between a variant in CAPN10 gene and the response to metformin therapy in patients with type 2 diabetes. This observation needs to be replicated in further studies in different populations.
Authors: S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews Journal: Diabetologia Date: 2012-04-20 Impact factor: 10.122
Authors: Mette M H Christensen; Charlotte Brasch-Andersen; Henrik Green; Flemming Nielsen; Per Damkier; Henning Beck-Nielsen; Kim Brosen Journal: Pharmacogenet Genomics Date: 2011-12 Impact factor: 2.089
Authors: Søren K Rasmussen; Søren A Urhammer; Lars Berglund; Jan N Jensen; Lars Hansen; Søren M Echwald; Knut Borch-Johnsen; Yukio Horikawa; Hirosato Mashima; Hans Lithell; Nancy J Cox; Torben Hansen; Graeme I Bell; Oluf Pedersen Journal: Diabetes Date: 2002-12 Impact factor: 9.461
Authors: Y Horikawa; N Oda; N J Cox; X Li; M Orho-Melander; M Hara; Y Hinokio; T H Lindner; H Mashima; P E Schwarz; L del Bosque-Plata; Y Horikawa; Y Oda; I Yoshiuchi; S Colilla; K S Polonsky; S Wei; P Concannon; N Iwasaki; J Schulze; L J Baier; C Bogardus; L Groop; E Boerwinkle; C L Hanis; G I Bell Journal: Nat Genet Date: 2000-10 Impact factor: 38.330
Authors: I Tkáč; L Klimčáková; M Javorský; M Fabianová; Z Schroner; H Hermanová; E Babjaková; R Tkáčová Journal: Diabetes Obes Metab Date: 2012-09-09 Impact factor: 6.577
Authors: James Rhee; Yusuke Inoue; J Cliff Yoon; Pere Puigserver; Melina Fan; Frank J Gonzalez; Bruce M Spiegelman Journal: Proc Natl Acad Sci U S A Date: 2003-03-21 Impact factor: 11.205
Authors: Kathleen A Jablonski; Jarred B McAteer; Paul I W de Bakker; Paul W Franks; Toni I Pollin; Robert L Hanson; Richa Saxena; Sarah Fowler; Alan R Shuldiner; William C Knowler; David Altshuler; Jose C Florez Journal: Diabetes Date: 2010-08-03 Impact factor: 9.461
Authors: Anila K Madiraju; Derek M Erion; Yasmeen Rahimi; Xian-Man Zhang; Demetrios T Braddock; Ronald A Albright; Brett J Prigaro; John L Wood; Sanjay Bhanot; Michael J MacDonald; Michael J Jurczak; Joao-Paulo Camporez; Hui-Young Lee; Gary W Cline; Varman T Samuel; Richard G Kibbey; Gerald I Shulman Journal: Nature Date: 2014-05-21 Impact factor: 49.962
Authors: Guozhi Jiang; Andrea O Luk; Claudia H T Tam; Eric S Lau; Risa Ozaki; Elaine Y K Chow; Alice P S Kong; Cadmon K P Lim; Ka Fai Lee; Shing Chung Siu; Grace Hui; Chiu Chi Tsang; Kam Piu Lau; Jenny Y Y Leung; Man-Wo Tsang; Grace Kam; Ip Tim Lau; June K Li; Vincent T Yeung; Emmy Lau; Stanley Lo; Samuel K S Fung; Yuk Lun Cheng; Chun Chung Chow; Ewan R Pearson; Wing Yee So; Juliana C N Chan; Ronald C W Ma Journal: PLoS Med Date: 2020-07-28 Impact factor: 11.069
Authors: Wishwanath R A Patkee; Georgina Carr; Emma H Baker; Deborah L Baines; James P Garnett Journal: J Cell Mol Med Date: 2016-02-02 Impact factor: 5.310